https://www.clinicalobserver.com/research/sacituzumab-tirumotecan-plus-pembrolizumab-improves-pfs-in-pd-l1-negative-nsclcClinical Observeren2026-10-25T18:29:17.844ZSacituzumab tirumotecan plus pembrolizumab improves PFS in PD-L1-negative NSCLChttps://www.clinicalobserver.com/public-health/nigeria-reports-first-bundibugyo-ebola-case-as-global-outbreak-tops-9-700Clinical Observeren2026-10-25T18:13:00.427ZNigeria Reports First Bundibugyo Ebola Case as Global Outbreak Tops 9,700https://www.clinicalobserver.com/biotech/tarlatamab-plus-durvalumab-cut-death-risk-58-in-first-line-small-cell-lungClinical Observeren2026-10-25T12:59:25.972ZTarlatamab plus durvalumab cut death risk 58% in first-line small cell lung cancerhttps://www.clinicalobserver.com/public-health/uganda-imposes-21-day-quarantine-on-citizens-returning-from-drcClinical Observeren2026-10-25T12:25:43.939ZUganda imposes 21-day quarantine on citizens returning from DRChttps://www.clinicalobserver.com/public-health/three-die-in-suspected-hantavirus-outbreak-on-atlantic-cruise-shipClinical Observeren2026-10-24T21:16:15.915ZThree die in suspected hantavirus outbreak on Atlantic cruise shiphttps://www.clinicalobserver.com/research/first-ebola-vaccine-trial-in-dr-congo-begins-in-buniaClinical Observeren2026-10-24T15:59:21.800ZFirst Ebola vaccine trial in DR Congo begins in Bunia